Scientists at Peter Mac and Cardiff University have identified an important genetic driver of aggressive prostate cancer, which may provide a new target to develop improved treatment.
Men with low risk prostate cancer, and their partners, are needed to take part in a study which is assessing a new online tool designed to help navigate their treatment.
Chief Executive Dale Fisher has announced that she will be leaving Peter MacCallum Cancer Centre to take on a national leadership role as CEO of Silver Chain, a leading home health and aged care provider.
An international clinical trial - led by Peter Mac’s Professor Michael MacManus - has shown that a combination therapy significantly improves long-term disease control for patients with localised, follicular lymphoma compared to radiotherapy alone. Follicular lymphoma is the most common type of low-grade lymphoma and it is a slow progressing disease, making clinical trials difficult to conduct.
A Peter Mac clinical trial using a highly advanced, single-dose radiotherapy treatment has halted the spread of prostate cancer in some men, delaying the need for conventional lifelong hormone therapy.
A compilation of scans of eight Peter Mac patients, created by Professor Michael Hofman and his research team, has been declared “Image of the Year” by the Society of Nuclear Medicine and Molecular Imaging.
Peter Mac scientists have described in unprecedented detail how the immune system responds to breast cancer, identifying a potential new target for immunotherapy treatments.